Why the best product doesn’t always win the contract Picture this: You’ve got the most potent flower, the cleanest extracts, and lab results that would make a scientist weep with joy. Yet somehow, your competitor with «decent» products just landed that massive dispensary contract you’ve been chasing for months. Welcome to cannabis B2B, where relationships trump perfection every single time.

The patterns most B2B cannabis companies notice but don’t discuss Picture this: It’s January, your cannabis inventory is overflowing, and your cash flow looks like a deflated balloon. Sound familiar? You’re not alone in this seasonal rollercoaster that defines the European medical cannabis market. Most B2B cannabis companies whisper about these patterns in boardrooms but rarely discuss them openly. Yet

The Insurance Gap: Why Cannabis B2B Companies Struggle with Coverage in Europe (And What Actually Works) Picture this: You’ve built a promising cannabis B2B company in Amsterdam, your hemp products are gaining traction across the EU, and then reality hits. Your insurance application gets rejected faster than a tourist trying to buy cannabis in a Dutch coffee shop. Welcome to

he cannabis testing landscape is evolving faster than a Amsterdam coffee shop queue on a Saturday night. Remember when cannabis testing was just about THC and CBD percentages? Those days are as outdated as flip phones and dial-up internet. Today’s European medical cannabis buyers aren’t just asking for the basics – they’re demanding comprehensive terpene profiles, full spectrum analysis, and

he green rush meets the red tape – and your bank account is caught in the crossfire. The Great Banking Blackout: Why Cannabis B2B Gets the Cold Shoulder The Regulatory Maze That Banks Can’t Navigate European cannabis businesses know the drill all too well. You’ve got your licenses sorted, compliance boxes ticked, and products ready to roll. Then you walk

It’s 2 AM and you just got the call. Your primary cannabis supplier has failed their EU-GMP audit. Your entire production schedule is now in jeopardy. The voice on the other end is apologetic but firm. «We need to halt all shipments immediately.» Your heart sinks as you realize thousands of patients depend on your products. This nightmare scenario plays